U.S. SECURITIES AND EXCHANGEEXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTIONSECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30,March 31, 20189

or

TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

 

For the Transition Period from              to

 

Commission file number 1-13463

 

BIO-KEY INTERNATIONAL, INC.

(Exact Name of Registrantregistrant as Specifiedspecified in Its Charter)its charter)

 

DELAWARE

41-1741861

(State or Other Jurisdiction of
Incorporation of Organization)

(IRS Employer
Identification Number)

 

3349 HIGHWAY 138, BUILDING A, SUITE E, WALL, NJ  07719

(Address of Principal Executive Offices)

 

(732) 359-1100

(Issuer’s Telephone Number)Registrant’s telephone number, including area code)

Securities registered pursuance to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

BKYI

Nasdaq Stock market

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒    No  ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒    No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ☐

Accelerated filer  ☐

 

Non-accelerated filer  ☐

Smaller Reporting Company  ☒

 

Non-accelerated filer ☐ (Do not check if a smaller reporting company)

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act)  Yes  ☐   No  ☒

 

Number of shares of Common Stock, $.0001 par value per share, outstanding as of AugustMay 13, 2018 is 12,591,279. 2019 was 14,081,688.

 

 

 

 

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY

 

INDEX

 

PART I. FINANCIAL INFORMATION

 

 

Item 1 — Condensed Consolidated Financial Statements (unaudited):

 Balance Sheets as of March 31, 2019 (unaudited) and December 31, 2018 (audited)

3

 Statements of Operations for the three months ended March 31, 2019 and 2018

4

 Statements of Stockholders’ Equity for the three months ended March 31, 2019 and 2018

5

 Statements of Cash Flows for the three months ended March 31, 2019 and 2018

7

 Notes to Condensed Consolidated Financial Statements

9

 

 

Item 12 — Management’s Discussion and Analysis of Financial Condition and Results of Operations. 

21

Financial Statements.

 

Item 4 — Controls and Procedures. 

27

PART II. OTHER INFORMATION

 

 

Condensed consolidated balance sheets as of June 30, 2018 (unaudited) and December 31, 2017Item 6 — Exhibits.  

327

 

 

Condensed consolidated statements of operations for the three and six months ended June 30, 2018 and 2017 (unaudited)

4

Signatures

28

Condensed consolidated statements of cash flows for the six months ended June 30, 2018 and 2017 (unaudited)

5

Notes to condensed consolidated financial statements (unaudited)

7

Item 2

Management’s Discussion and Analysis of Financial Conditions and Results of Operations.

19

Item 4

Controls and Procedures.

26

PART II. OTHER INFORMATION

Item 2

Unregistered Sales of Equity Securities and Use of Proceeds.

26

Item 6

Exhibits.

26

Signatures

27


PART I -- FINANCIAL INFORMATION

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

  

June 30,

2018

  

December 31,

2017

 
  

(Unaudited)

     

ASSETS

        

Cash and cash equivalents

 $304,006  $288,721 

Accounts receivable, net

  491,651   2,875,946 

Due from factor

  27,663   109,865 

Inventory

  930,478   946,847 

Resalable software license rights

  2,820,000   2,640,000 

Prepaid expenses and other

  156,695   152,654 

Total current assets

  4,730,493   7,014,033 

Resalable software license rights, net of current portion

  6,425,706   7,933,808 

Accounts receivable, net of current portion

  720,000   760,000 

Equipment and leasehold improvements, net

  189,360   181,165 

Capitalized contract costs, net

  341,622   - 

Deposits and other assets

  8,712   8,712 

Intangible assets, net

  187,826   181,104 

Total non-current assets

  7,873,226   9,064,789 

TOTAL ASSETS

 $12,603,719  $16,078,822 
         

LIABILITIES

        

Accounts payable

 $330,431  $499,230 

Accrued liabilities

  484,578   688,023 

Dividends payable

  -   630,408 

Deferred revenue

  328,183   507,866 

Total current liabilities

  1,143,192   2,325,527 

TOTAL LIABILITIES

  1,143,192   2,325,527 
         

Commitments and contingencies

        
         

STOCKHOLDERS’ EQUITY

        
         

Series A-1 convertible preferred stock: authorized, 100,000 (liquidation preference of $100 per share); issued and outstanding 0 and 62,596 of $.0001 par value at June 30, 2018 and December 31, 2017, respectively

  -   6 

Series B-1 convertible preferred stock; authorized, 105,000 (liquidation preference of $100 per share): issued and outstanding 0 and 105,000 of $.0001 par value at June 30, 2018 and December 31, 2017, respectively

  -   11 

Common stock: authorized, 170,000,000 shares; issued and outstanding; 12,587,997 and 7,691,324 of $.0001 par value at June 30, 2018 and December 31, 2017, respectively

  1,259   769 

Additional paid-in capital

  82,143,199   80,829,001 

Accumulated deficit

  (70,683,931

)

  (67,076,492

)

TOTAL STOCKHOLDERS’ EQUITY

  11,460,527   13,753,295 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $12,603,719  $16,078,822 

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

 


 

 

PART I — FINANCIAL INFORMATION

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY

International, Inc. and Subsidiary
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)BALANCE SHEETS

 

  

Three months ended

June 30,

  

Six months ended

June 30,

 
  

2018

  

2017

  

2018

  

2017

 

Revenues

                

Services

 $249,121  $134,061  $551,570  $454,648 

License fees

  154,251   127,751   256,970   624,319 

Hardware

  344,769   625,069   781,056   1,226,249 
Total revenues  748,141   886,881   1,589,596   2,305,216 

Costs and other expenses

                

Cost of services

  120,841   55,660   275,573   94,480 

Cost of license fees, hardware, and other

  908,962   740,301   1,933,675   1,362,415 
Total costs and other expenses  1,029,803   795,961   2,209,248   1,456,895 

Gross profit (loss)

  (281,662

)

  90,920   (619,652

)

  848,321 
                 

Operating Expenses

                

Selling, general and administrative

  1,076,184   1,431,208   2,538,038   3,051,358 

Research, development and engineering

  297,633   449,049   689,787   942,493 

Total Operating Expenses

  1,373,817   1,880,257   3,227,825   3,993,851 

Operating loss

  (1,655,479

)

  (1,789,337

)

  (3,847,477

)

  (3,145,530

)

Other income

                

Interest income

  14   8   21   14 

Total other income

  14   8   21   14 

Net loss

  (1,655,465

)

  (1,789,329

)

  (3,847,456

)

  (3,145,516

)

Convertible preferred stock dividends

  (41,870

)

  (200,625

)

  (198,033

)

  (401,250

)

Net loss available to common stockholders

 $(1,697,335

)

 $(1,989,954

)

 $(4,045,489

)

 $(3,546,766

)

                 

Basic and Diluted Loss per Common Share

 $(0.15

)

 $(0.32

)

 $(0.42

)

 $(0.57

)

                 

Weighted Average Shares Outstanding:

                

Basic and diluted

  11,375,320   6,359,974   9,623,151   6,228,197 

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements. 


  

March 31,

2019

  

December 31,

2018

 
  

(Unaudited)

     

ASSETS

        

Cash and cash equivalents

 $459,311  $323,943 

Accounts receivable, net

  740,419   1,574,032 

Due from factor

  75,824   56,682 

Inventory

  980,908   998,829 

Resalable software license rights

  1,125,000   1,125,000 

Prepaid expenses and other

  175,144   150,811 

Total current assets

  3,556,606   4,229,297 

Resalable software license rights, net of current portion

  6,483,406   6,790,610 

Equipment and leasehold improvements, net

  152,707   148,608 

Capitalized contract costs, net

  299,398   319,199 

Deposits and other assets

  8,712   8,712 

Operating lease right-of-use assets

  568,073   - 

Intangible assets, net

  194,330   195,906 

Total non-current assets

  7,706,626   7,463,035 

TOTAL ASSETS

 $11,263,232  $11,692,332 
         

LIABILITIES

        

Accounts payable

 $472,629  $481,269 

Accounts payable – related party

  133,174   - 

Accrued liabilities

  577,996   548,232 

Deferred revenue

  333,240   196,609 

Operating lease liabilities, current portion

  138,274   - 

Total current liabilities

  1,655,313   1,226,110 

Operating lease liabilities, net of current portion

  419,171   - 

Total non-current liabilities

  419,171   - 

TOTAL LIABILITIES

  2,074,484   1,226,110 
         

Commitments

        

STOCKHOLDERS’ EQUITY

        
         

Common stock — authorized, 170,000,000 shares; issued and outstanding; 13,991,688 and 13,977,868 of $.0001 par value at March 31, 2019 and December 31, 2018, respectively

  1,399   1,398 

Additional paid-in capital

  86,125,173   85,599,140 

Accumulated deficit

  (76,937,824

)

  (75,134,316

)

TOTAL STOCKHOLDERS’ EQUITY

  9,188,748   10,466,222 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $11,263,232  $11,692,332 

 

 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

  

Six Months Ended June 30,

 
  

2018

  

2017

 
         

CASH FLOW FROM OPERATING ACTIVITIES:

        

Net loss

 $(3,847,456

)

 $(3,145,516

)

Adjustments to reconcile net loss to net cash provided by (used for) operating activities:

        

Bad debt expense

  -   500,000 

Depreciation

  44,596   15,513 

Amortization of intangible assets

  8,966   6,833 

Amortization of resalable software license rights

  1,318,559   729,755 

Amortization of capitalized contract costs

  59,044   - 

Share-based and warrant compensation for employees and consultants

  676,454   564,275 

Stock based directors fees

  23,021   10,008 

Change in assets and liabilities:

        

Accounts receivable

  2,424,295   715,357 

Due from factor

  82,202   24,176 

Capitalized contract costs

  (160,649

)

  - 

Inventory

  16,369   (101,754

)

Resalable software license rights

  9,543   75,648 

Prepaid expenses and other

  (4,041

)

  16,556 

Accounts payable

  (168,799

)

  (133,215

)

Accrued liabilities

  (203,445

)

  86,027 

Deferred revenue

  (179,683

)

  (215,598

)

Net cash provided by (used for) operating activities

  98,976   (851,935

)

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Capital expenditures

  (68,479

)

  (140,664

)

Net cash used for investing activities

  (68,479

)

  (140,664

)

CASH FLOW FROM FINANCING ACTIVITIES:

        

Issuance of common stock

  -   1,000,000 

Costs to issue preferred and common stock

  (15,212

)

  (80,366

)

Net cash provided by (used for) financing activities

  (15,212

)

  919,634 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

  15,285   (72,965

)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

  288,721   1,061,307 

CASH AND CASH EQUIVALENTS, END OF PERIOD

 $304,006  $988,342 

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements. 

 


 

BIO-KEY International,International, Inc. and Subsidiary
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

  

Three months ended
March 31,

 
  

2019

  

2018

 
         

Revenues

        

Services

 $241,610  $302,449 

License fees

  83,208   102,719 

Hardware

  226,805   436,287 
   551,623   841,455 

Costs and other expenses

        

Cost of services

  90,829   154,733 

Cost of license fees

  377,216   773,464 
Cost of hardware  136,005   251,248 
   604,050   1,179,445 

Gross Profit (Loss)

  (52,427

)

  (337,990)
         

Operating Expenses

        

Selling, general and administrative

  1,377,033   1,461,854 

Research, development and engineering

  374,118   392,154 

Total Operating Expenses

  1,751,151   1,854,008 

Operating loss

  (1,803,578

)

  (2,191,998

)

Other income (expenses)

        

Interest income

  70   6 

Total Other Income (Expenses)

  70   6 

Net loss

  (1,803,508

)

  (2,191,992

)

Convertible preferred stock dividends

  -   (156,162

)

Net loss available to common stockholders

 $(1,803,508

)

 $(2,348,154

)

         

Basic & Diluted Loss per Common Share

 $(0.13

)

 $(0.30

)

         

Weighted Average Shares Outstanding:

        

Basic & Diluted

  13,979,318   7,851,514 

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.


BIO-key International, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

  

Series A-1

Preferred Stock

  

Series B-1

Preferred Stock

  

Common Stock

  

Additional

Paid-in

  

Accumulated

     
  

Shares

  

Amount

  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Deficit

  

Total

 

Balance as of December 31, 2018

  -  $-   -  $-   13,977,868  $1,398  $85,599,140  $(75,134,316

)

 $10,466,222 

Issuance of common stock for directors’ fees

  -   -   -   -   13,820   1   16,505   -   16,506 

Share-based compensation

  -   -   -   -   -   -   509,528   -   509,528 

Net loss

                              (1,803,508

)

  (1,803,508

)

Balance as of March 31, 2019

  -  $-   -  $-   13,991,688  $1,399  $86,125,173  $(76,937,824

)

 $9,188,748 

 The accompanying notes are an integral part of these statements.


BIO-key International, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

  

Series A-1

Preferred Stock

  

Series B-1

Preferred Stock

  

Common Stock

  

Additional

Paid-in

  

Accumulated

     
  

Shares

  

Amount

  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Deficit

  

Total

 

Balance as of December 31, 2017

  62,596  $6   105,000  $11   7,691,324  $769  $80,829,001  $(67,076,492

)

 $13,753,295 

Adoption of ASC 606

  -   -   -   -   -   -   -   240,017   240,017 

Issuance of common stock for directors’ fees

  -   -   -   -   8,421   1   16,512   -   16,513 

Dividends declared on preferred stock

  -   -   -   -   -   -   (156,162

)

  -   (156,162

)

Conversion of B-1 preferred stock to common stock

  -   -   (60,420

)

  (6

)

  1,678,334   168   (162

)

  -   - 

Conversion of dividends payable on B-1 preferred stock

  -   -   -   -   115,857   11   417,072   -   417,083 

Share-based compensation

  -   -   -   -   -   -   533,421       533,421 

Net loss

                              (2,191,992

)

  (2,191,992

)

Balance as of March 31, 2018

  62,596  $6   44,580  $5   9,493,936  $949  $81,639,682  $(69,028,467

)

 $12,612,175 

The accompanying notes are an integral part of these statements.


BIO-KEY International, Inc. and Subsidiary
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

  

Three Months Ended March 31,

 
  

2019

  

2018

 
         

CASH FLOW FROM OPERATING ACTIVITIES:

        

Net loss

 $(1,803,508

)

 $(2,191,992

)

Adjustments to reconcile net loss to cash provided by operating activities:

        

Depreciation

  19,292   21,020 

Amortization of intangible assets

  3,314   5,655 

Amortization of software license rights

  281,074   659,414 

Amortization of capitalized contract costs

  33,510   18,668 

Operating leases right-of-use assets

  34,864   - 

Stock based directors’ fees

  16,505   16,512 

Share and warrant-based compensation for employees and consultants

  509,528   533,421 

Change in assets and liabilities:

        

Accounts receivable

  833,613   2,590,770 

Due from factor

  (19,142

)

  55,820 

Capitalized contract costs

  (13,709

)

  (144,018

)

Inventory

  17,921   47,687 

Resalable software license rights

  26,130   (11,954

)

Prepaid expenses and other

  (36,928

)

  (14,221

)

Accounts payable

  124,534   (246,245

)

Accrued liabilities

  29,764   (163,343

)

Deferred revenue

  136,631   (133,427

)

Operating lease liabilities

  (32,897

)

  - 

Net cash provided by operating activities

  160,496   1,043,767 

CASH FLOW FROM INVESTING ACTIVITIES:

        

Purchase of intangible assets

  (1,737

)

  - 

Capital expenditures

  (23,391

)

  (32,857

)

Net cash used for investing activities

  (25,128

)

  (32,857

)

NET INCREASE IN CASH AND CASH EQUIVALENTS

  135,368   1,010,910 

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

  323,943   288,721 

CASH AND CASH EQUIVALENTS, END OF PERIOD

 $459,311  $1,299,631 

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.


BIO-KEY International, Inc. and Subsidiary
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 

SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

 

  

Six Months Ended June 30,

 
  

2018

  

2017

 
         

Cash paid for:

        

Interest

 $  $ 
Income taxes $  $ 
         

Noncash investing and financing activities

        

Accrual of unpaid dividends on preferred stock

 $198,033  $401,250 

Conversion of A-1 preferred dividends payable to common stock

 $356,015  $ 

Conversion of A-1 preferred stock to common stock

 $6,259,600  $ 

Conversion of B-1 preferred dividends payable to common stock

 $472,426  $ 

Conversion of B-1 preferred stock to common stock

 $10,500,000  $ 

Issuance of common stock for consultancy services

 $  $114,585 
  

Three Months Ended March 31,

 
  

2019

  

2018

 
         

Cash paid for:

        

Interest

 $  $ 
         

Noncash Investing and financing activities

        

Accrual of unpaid preferred stock dividends

 $  $156,162 

Conversion of B-1 preferred dividends payable to common stock

 $  $417,084 

Conversion of B-1 preferred stock to common stock

 $  $6,042,000 

Right-of-use asset addition under ASC 842

 $602,937  $ 

Operating lease liabilities under ASC 842

 $590,342  $ 

 

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

 


 

BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARYInternational Inc., and Subsidiary

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30,March 31, 20189 (Unaudited)

 

 

1.

NATURE OF BUSINESS AND BASIS OF PRESENTATION

 

Nature of Business

BIO-key International, Inc.,The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit card, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

��

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiary (collectively, the “Company” or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.

 

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at June 30, 2018March 31, 2019 was derived from the audited financial statements, but does not include all of the disclosures required by accounting principles generally accepted in the United States of America. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017,2018, filed with the SEC on April 2, 2018. 1, 2019. 

Updated Significant Accounting Policies

 

Recently Issued Accounting PronouncementsLeases

In May 2014, ASU No. 2014-09, “Revenue from Contracts with Customers” was issued. The Company adopted ASU 2014-09 and its related amendments (collectively known as ASC 606) effective on January 1, 2018 using the modified retrospective method. Please see Note 3 "Revenue from Contracts with Customers" for the required disclosures related to the impact of adopting this standard and a discussion of the Company's updated policies related to revenue recognition and accounting for costs to obtain and fulfill a customer contract.

 

In February 2016, the FASBFinancial Accounting Standards Board (FASB) issued ASUAccounting Standards Update (ASU) 2016-02, “Leases” (Topic 842), as amended (ASC 842).  The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classifiedmonths and classify as either operating or finance leases.  We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date.  Adoption of the ASC 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities.  There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC 842), therefore there was no change in accounting treatment required.  For comparability purposes, we will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated.

We elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases.


In accordance with ASC 842, at the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use (ROU) assets, lease liabilities and, if applicable, long-term lease liabilities. We have elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, we have elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and therefore we use the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of our incremental borrowing rate requires judgment. We determine our incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with classification affecting the patternterms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.

For periods prior to the adoption of ASC 842, we recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented.

The impact of the income statement.adoption of ASC 842 on the balance sheet was:

 

 

As reported

  

Adoption of ASC

   Balance 

 

 

December 31,

2018

  

842 - increase

(decrease)

   

January 1,

2019

 

Operating lease right-of-assets

 $-  $602,937  $602,937 

Prepaid expenses and other

 $150,811  $(12,595) $138,216 

Total assets

 $11,692,332  $590,342  $12,282,674 

Operating lease liabilities, current portion

 $-  $135,519  $135,519 

Operating lease liabilities, net of current portion

 $-  $454,823  $454,823 

Total liabilities

 $1,226,110  $590,342  $1,816,452 

Total liabilities and stockholders’ equity

 $11,692,332  $590,342  $12,282,674 

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract(“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The newupdate to the standard is effective for fiscal yearsinterim and annual periods beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at,2019, with early adoption permitted. Entities can choose to adopt the ASU 2018-15 prospectively or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available.retrospectively. The Company is currently evaluatingassessing the impact of its pending adoption of the new standardASU 2018-15 will have on its consolidated financial statements, and expects that it will increase its assets and liabilities for amounts yet to be determined.statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Under ASU 2017-11, down round features do not meet the criteria for derivative accounting and no liability is to be recorded until an actual issuance of securities triggers the down-round feature. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. The adoption of ASU 2017-11, during the fiscal 2017 year did not have any impact on the condensed consolidated financial statements, however our disclosures with respect to equity instruments with down round features have been updated.   


  

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

Reclassification

Reclassifications
Reclassification occurred to certain prior year amounts in order to conform to the current year classifications including segregating the hardware revenues.classifications.  The reclassifications have no effect on the reported net loss.

 

 

2.

GOING CONCERN

 

The Company has incurred significant losses to date, and at June 30, 2018March 31, 2019 had an accumulated deficit of approximately $71$77 million. In addition, broad commercial acceptance of the Company’s technology is critical to the Company’s success and ability to generate future revenues. At June 30, 2018,March 31, 2019, the Company’s total cash and cash equivalents were approximately $304,000,$459,000, as compared to approximately $289,000$324,000 at December 31, 2017.2018.


 

The Company has financed operations in the past through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company estimates that it currently requires approximately $592,000$537,000 per month to conduct operations, a monthly amount that it has been unable to achieve consistently through revenue generation.

 

If the Company is unable to generate sufficient revenue to meet its goals, it will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute its plan to substantially grow operations, increase revenue, and serve a significant customer base; and (ii) provide working capital. No assurance can be given that any form of additional financing will be available on terms acceptable to the Company, that adequate financing will be obtained by the Company, in order to meet its needs, or that such financing would not be dilutive to existing shareholders.

 

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The matters described in the preceding paragraphs raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, and become profitable in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

 

 

 

3.

REVENUE FROM CONTRACTS WITH CUSTOMERS

 

The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP" or the "previous guidance". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services and will provide financial statement readers with enhanced disclosures. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps:

 

 

Identify the contract with a customer

 

Identify the performance obligations in the contract

 

Determine the transaction price

 

Allocate the transaction price to performance obligations in the contract

 

Recognize revenue when or as the Company satisfies a performance obligation

 


Disaggregation of Revenue

The following table summarizes revenue from contracts with customers for the three month periodsperiod ended:

 

 

North

America

  

South

America

  

EMEA*

  

Asia

  

June 30,

2018

  

North

America

  

South

America

  

EMEA*

  

Asia

  

March 31,

2019

 
                                        

License fees

 $69,151  $30,000  $55,100  $-  $154,251  $14,208  $-  $-  $69,000  $83,208 

Hardware

  120,496   53,040   10,298   160,935   344,769   45,981   400   32,918   147,506   226,805 

Support and Maintenance

  225,602   16   12,503   3,000   241,121   195,326   2,116   36,418   5,000   238,860 

Professional services

  6,000   -   2,000   -   8,000   750   -   -   2,000   2,750 

Total Revenues

 $421,249  $83,056  $79,901  $163,935  $748,141  $256,265  $2,516  $69,336  $223,506  $551,623 

 

  

North

America

  

South

America

  

EMEA*

  

Asia

  

June 30,

2017

 
                     

License fees

 $37,168  $583  $-  $90,000  $127,751 

Hardware

  359,732   2,011   590   262,736   625,069 

Support and Maintenance

  114,275   176   9,100   310   123,861 

Professional services

  4,800   -   -   5,400   10,200 

Total Revenues

 $515,975  $2,770  $9,690  $358,446  $886,881 

The following table summarizes revenue from contracts with customers for the six month periods ended:

  

North

America

  

South

America

  

EMEA*

  

Asia

  

June 30,

2018

 
                     

License fees

 $130,120  $30,000  $96,850  $-  $256,970 

Hardware

  220,086   53,040   225,074   282,856   781,056 

Support and Maintenance

  403,518   16   21,216   16,970   441,720 

Professional services

  107,850   -   2,000   -   109,850 

Total Revenues

 $861,574  $83,056  $345,140  $299,826  $1,589,596 

 

North

America

  

South

America

  

EMEA*

  

Asia

  

June 30,

2017

  

North

America

  

South

America

  

EMEA*

  

Asia

  

March 31,

2018

 
                                        

License fees

 $531,735  $583  $-  $92,000  $624,318  $60,969  $-  $41,750  $-  $102,719 

Hardware

  721,822   2,341   590   501,496   1,226,249   99,590   -   214,776   121,921   436,287 

Support and Maintenance

  247,701   245   15,295   708   263,949   177,916   -   8,713   13,970   200,599 

Professional services

  185,300   -   -   5,400   190,700   101,850   -   -   -   101,850 

Total Revenues

 $1,686,558  $3,169  $15,885  $599,604  $2,305,216  $440,325  $-  $265,239  $135,891  $841,455 

 

*EMEA – Europe, Middle East, Africa


 

All of the Company's performance obligations, and associated revenue, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.

 

Software licenses

Software license revenue consist of fees for perpetual software licenses for one or more of the Company’s biometric fingerprint solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.

 

Hardware

Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.

 

Support and Maintenance

Support and Maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its Support and Maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of invoiceprepayment until the contracts term occurs. Revenue is recognized over time on a ratable basis over the contract term. Support and Maintenance contracts are up to one year in length and are generally invoiced either annually or quarterly in advance.

 

Professional Services

Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.


 

Contracts with Multiple Performance Obligations

Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis.  The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.

 

The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.

 

Accounts receivable from customers are typically due within 30 days of invoicing.  The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.

 

Costs to Obtain and Fulfill a Contract

Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations.

 

Financial Statement Impact of Adopting ASC 606

The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date. The cost of obtaining the contract reflects the outcome of the sales effort in educating, demonstrating and selling our solutions. Accordingly under ASC 606, commissions are a capitalized cost due to the acquisition of a new customer.

As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to the following select condensed consolidated balance sheet line items as of January 1, 2018:

  

As reported -

December 31,

2017

  

Adjustments

  

As adjusted -

January 1, 2018

 
             

Capitalized contract assets

 $-  $240,017  $240,017 

Total assets

 $16,078,822  $240,017  $16,318,839 
             

Accumulated deficit

 $(67,076,492) $240,017  $(66,836,475

)

Total Stockholders’ Equity

 $13,753,295  $240,017  $13,993,312 

Total Liabilities and Stockholders’ Equity

 $16,078,822  $240,017  $16,318,839 

Impact of New Revenue Guidance on Financial Statement Line Items

The following table compares selected reported condensed consolidated balance sheet, statement of operations and cash flows, as of and for the three and six months ended June 30, 2018, to the pro-forma amounts had the previous guidance still been applied:

  

As of June 30, 2018

  
  

As reported

  

Pro-forma

  

Increase

(decrease)

  
              

Consolidated balance sheet data:

             
Capitalized contract costs, net $341,622  $-  $(341,622

)

 


  

Three Months Ended June 30, 2018

  

Six Months Ended June 30, 2018

 
  

As reported

  

Pro-forma

  

Increase

(decrease)

  

As reported

  

Pro-forma

  

Increase

(decrease)

 

Consolidated statement of operations data:

                        

Selling, general and administrative expenses

  1,076,184   1,052,439   (23,745

)

 $2,538,038  $2,639,643  $101,605 

Net loss

  (1,655,465

)

  (1,631,720

)

  23,745   (3,847,456

)

  (3,949,061

)

  (101,605

)

Net loss available to common stockholders

  (1,697,335

)

  (1,673,590

)

  23,745   (4,045,489

)

  (4,147,094

)

  (101,605

)

Basic & Diluted Loss per Common Share

  (0.15

)

  (0.15

)

  0.00   (0.42

)

  (0.43

)

  (0.01

)

  

Six Months Ended June 30, 2018

  
  

As reported

  

Pro-forma

  

Increase

(decrease)

  

Consolidated statement of cash flow data:

             

Net loss

  (3,847,456

)

  (3,949,061

)

  (101,605

)

 

Change in contract assets

  (101,605

)

  -   101,605  

Net cash provided by operating activities

  98,976   98,976   -  

Revenue recognized during the three and six months ended June 30, 2018March 31, 2019 from amounts included in deferred revenue at the beginning of the period was approximately $79,000 and $197,000 respectively.$76,000. The Company did not recognize any revenue from performance obligations satisfied in prior periods. Total deferred revenue (contract liability) was $328,183$333,240 and $507,866$196,609 at June 30, 2018March 31, 2019 and December 31, 2017,2018, respectively.

 


Transaction Price Allocated to the Remaining Performance Obligations

ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as at June 30, 2018.March 31, 2019. The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:

 

 

The performance obligation is part of a contract that has an original expected duration of one year or less, in accordance with ASC 606-10-50-14.

 

At June 30, 2018March 31, 2019 deferred revenue represents ourthe Company's remaining performance obligations related to prepaid support and maintenance, all of which is expected to be recognized within one year.

 

 

 

4.

ACCOUNTS RECEIVABLE

 

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible. As a result of the payment delays for a large customer, the Company has continued to reserve $1,000,000reserved $1,720,000 at June 30,March 31, 2019 and December 31, 2018, which represents 58%100% of the remaining balance owed under the contract.contract, respectively. Recoveries of accounts receivable previously written off are recorded when received. Accounts receivable at June 30, 2018March 31, 2019 and December 31, 20172018 consisted of the following:

 

 

June 30,

  

December 31,

 
 

2018

  

2017

  

March 31,

  

December 31,

 
         

2019

  

2018

 

Accounts receivable - current

 $505,436  $2,889,731  $754,204  $1,587,817 

Accounts receivable - non current

  1,720,000   1,760,000   1,720,000   1,720,000 
Total accounts receivable  2,225,436   4,649,731 
  2,474,204   3,307,817 

Allowance for doubtful accounts - current

  (13,785

)

  (13,785

)

  (13,785

)

  (13,785

)

Allowance for doubtful accounts - non current

  (1,000,000

)

  (1,000,000

)

  (1,720,000

)

  (1,720,000

)

Total allowance for doubtful accounts  (1,013,785

)

  (1,013,785

)

Accounts receivable, net of allowance for doubtful accounts

 $1,211,651  $3,635,946 
  (1,733,785

)

  (1,733,785

)

        

Accounts receivable, net of allowances for doubtful accounts

 $740,419  $1,574,032 

 


 

5.

SHARE BASED COMPENSATION

 

The following table presents share-based compensation expenses for continuing operations included in the Company’s unaudited condensed interim consolidated statements of operations:

 

 

Three Months Ended March 31,

 
 

Three Months Ended June 30,

  

2019

  

2018

 
 

2018

  

2017

         
                

Selling, general and administrative

 $128,620  $394,264  $453,086  $471,146 

Research, development and engineering

  20,922   18,930   72,947   78,787 
 $149,542  $413,194  $526,033  $549,933 

 

  

Six Months Ended June 30,

 
  

2018

  

2017

 
         

Selling, general and administrative

 $599,766  $507,120 

Research, development and engineering

  99,709   67,163 
  $699,475  $574,283 

  

 

6.

FACTORING

 

Due from factor consisted of the following as of: 

 

 

June 30,

  

December 31,

  

March 31,

  

December 31,

 
 

2018

  

2017

  

2019

  

2018

 
                

Original invoice value

 $118,494  $423,349  $302,777  $221,120 

Factored amount

  (90,831

)

  (313,484

)

  (226,953

)

  (164,438

)

Due from factor

 $27,663  $109,865 

Balance due from factor

 $75,824  $56,682 


 

The Company entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2018.2019. Pursuant to the terms of the arrangement, the Company, from time to time, sells to the Factor a minimum of $150,000 per quarter of certain of its accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to the Company (the “Advance Amount”), with the remaining balance, less fees to be forwarded to the Company once the Factor collects the full accounts receivable balance from the customer. In addition, the Company, from time to time, receives over advances from the factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored, and are determined by the number of days required for collection of the invoice. The cost of factoring is included in selling, general and administrative expenses. The cost of factoring was as follows:  

 

  

Three Months ended

June 30,

 
  

2018

  

2017

 
         

Factoring fees

 $12,691  $85,326 

  

Six Months ended

June 30,

 
  

2018

  

2017

 
         

Factoring fees

 $104,214  $133,717 
  

Three Months ended

March 31,

 
  

2019

  

2018

 
         

Factoring fees

 $52,797  $91,523 

 

 

 

7.

INVENTORY

 

Inventory is stated at the lower of cost, determined on a first in, first out basis, or net realizable value, and consists primarily of fabricated assemblies and finished goods. Inventory is comprised of the following as of:

  

  

June 30,

  

December 31,

 
  

2018

  

2017

 
         

Finished goods

 $408,984  $487,858 

Fabricated assemblies

  521,494   458,989 

Total inventory

 $930,478  $946,847 
  

March 31,

  

December 31,

 
  

2019

  

2018

 
         
         

Finished goods

 $476,418  $496,358 

Fabricated assemblies

  504,490   502,471 

Total inventory

 $980,908  $998,829 

 


��

 

8.

RESALABLE SOFTWARE LICENSE RIGHTS

 

On November 11, 2015, the Company entered into a license agreement for the rights to all software and documentation regarding the technology currently known as or offered under the FingerQ name. The license agreement grants the Company the exclusive right to reproduce, create derivative works and distribute copies of the FingerQ software and documentation, create new FingerQ related products, and grant sub-licenses of the licensed technology to end users. The license rights have been granted to the Company in perpetuity, with a stated number of end-user resale sub-licenses allowed under the contract for a total of $12,000,000. The cost of sub-license rights expected to be amortized in the following 12 months is $2,820,000$1,125,000 and is classified as current, with remainder as non-current.

 

The Company hasoriginally determined the software license rights to be a finite lived intangible asset, and estimated that the software license rights shall be economically used over a 10 year period, with a weighting towards the beginning years of that time-frame. The license rights were acquired during the fourth quarter of 2015, but the usage of such rights in the Company’s products was not generally available until January 2017. Accordingly, amortization began in the first quarter of 2017.

 

TheThrough 2018, the remaining license rights arewere to be amortized over the greater of the following:following amounts: 1) an estimate of the economic use of such license rights, 2) the amount calculated by the straight line method over ten years or 3) the actual cost basis of sales usage of such rights. The Company believes that the economic use model was front-end focused as a majority of the expected up-take of the FingerQ technology was predicted to occur during the first 4-5 years of the 10-year life cycle of the product. Based on current sales trends, the Company now believes future transactions will be more evenly dispersed over the remaining life cycle of the product, indicating that the greater of the straight-line methodology or or actual unit cost per license sold will more closely align the expense with the remaining useful life of the product. The change in amortization was effective beginning on January 1, 2019 based on the net remaining software license rights balance. The Company believes categorizing the amortization expense under Cost of Sales more closely reflects the nature of the license right arrangement and the use of the technology. A total of $281,250 and $660,000 and $390,000 was expensedcharged to cost of sales during the three month periods ended June 30,March 31, 2019 and 2018, respectively and 2017,of this amount $176 and $586, represent the cost basis of the actual sales, respectively. A total of $1,320,000 and $778,092 was expensed during the six month periods ended June 30, 2018 and 2017, respectively.  The 2018 expense was recorded based on the economic use model. Since the license purchase, a cumulative amount of $2,878,596$4,479,846 has been expensed,charged to cost of sales, with a carrying balance of $9,121,404$7,520,154 as of June 30, 2018.March 31, 2019. The Company's change in methodology was determined to be a change in accounting estimate that is effected by a change in accounting principle.  Pursuant to ASC 250-10-45-17 guidance, this accounting change will not be accounted for as a cumulative effect adjustment on the statement of operations in the period of change and there will be no retroactive application or restatement of prior periods.  Instead, the Company allocates the remaining unamortized balance over the remaining life of the assets using the newly adopted method.


The following compares line items on the statement of operations had the change in amortization methodology not been made:

  

As reported

  

Prior methodology

 
  

3 months ended

  3 months ended 
  

March 31, 2019

  March 31, 2019 

Amortization of software license rights

 $281,074  $749,824 

Total operating expenses

 $1,751,151  $2,219,901 

Operating loss

 $(1,803,578) $(2,272,328)

Net loss

 $(1,803,508) $(2,272,258)

Basic & diluted loss per share

 $(0.13) $(0.16)

 

On December 31, 2015, the Company purchased third-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company is amortizing the total cost over the same methodology described above with the greatest of the threetwo approaches being the amortization for the periods.actual unit cost per license sold. A total of $20,642 and $22,020$25,954 was expensedcharged to cost of sales during the three month periodsperiod ended June 30, 2018March 31, 2019, and 2017, respectively. A totala net credit of $8,102 (net of credits of $14,400) and $28,716$12,540 was expensedrecorded during the six month periods ended June 30, 2018 and 2017,period, respectively. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of $55,698 net of credits$91,748 has been expensed,charged to cost of sales, with a carrying balance of $124,302$88,252 as of June 30, 2018.March 31, 2019. The Company has classified the balance as non-current until a larger deployment occurs. Software license rights is comprised of the following as of:

 

  

June 30,

  

December 31,

 
  

2018

  

2017

 
         
         

Current resalable software license rights

 $2,820,000  $2,640,000 

Non-current resalable software license rights

  6,425,706   7,933,808 

Total resalable software license rights

 $9,245,706  $10,573,808 
  

March 31,

  

December 31,

 
  

2019

  

2018

 
         

Current software license rights

 $1,125,000  $1,125,000 

Non-current software license rights

  6,483,406   6,790,610 

Total software license rights

 $7,608,406  $7,915,610 

  

 

9.

Related Party

During the quarter ended March 31, 2019, the Company received a non-interest bearing advance from an executive officer/director, the Company's principal stockholder, in amount of $133,174 to pay current liabilities. The advance is payable upon demand.

10.

LEASES

The Company’s leases office space in New Jersey, Hong Kong and Minnesota with lease termination dates of 2023, 2019, and 2020, respectively. The Minnesota lease is under 12 months, thus classified as short-term and not reported on the balance sheet under ASC 842. The Hong Kong and the New Jersey leases include non-lease components with variable payments. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases, for the three months ended and as of:

  

March 31,

 
  

2019

 
     

Lease cost

    

Operating lease cost

 $42,981 

Short-term lease cost

  16,295 

Sublease income

  - 

Total lease cost

 $59,276 
     

Balance sheet information

    

Operating ROU assets

 $568,073 
     

Operating lease liabilities, current portion

 $138,274 

Operating lease liabilities, non-current portion

  419,171 

Total operating lease liabilities

 $557,445 
     

Weighted average remaining lease term (in years) – operating leases

  4.11 

Weighted average discount rate – operating leases

  5.50

%

Supplemental cash flow information related to leases were as follows, for the three months ended March 31, 2019:

Cash paid for amounts included in the measurement of operating lease liabilities

$42,030


Maturities of operating lease liabilities were as follows:

2019 (remaining nine months)

 $124,231 

2020

  155,682 

2021

  127,425 

2022

  131,249 

2023

  89,226 

2024 and thereafter

  - 

Total future lease payments

 $627,813 

Less: imputed interest

  (70,368

)

Total

 $557,445 

11.

EARNINGS (LOSS) PER SHARE - COMMON STOCK (“EPS”)

 

The Company’s basic EPS is calculated using net lossincome (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of convertible preferred stock.

 

The reconciliation of the numerator of the basic and diluted EPS calculations was as follows for both of the following three and six month periods ended June 30, 2018March 31, 2019 and 2017:2018:

 

  

Three Months ended

June 30,

  

Six Months ended

June 30,

 
  

2018

  

2017

  

2018

  

2017

 

Basic Numerator:

                
                 

Net loss

 $(1,655,465

)

 $(1,789,329

)

 $(3,847,456

)

 $(3,145,516

)

Convertible preferred stock dividends

  (41,870

)

  (200,625

)

  (198,033

)

  (401,250

)

Net loss available to common stockholders

 $(1,697,335

)

 $(1,989,954

)

 $(4,045,489

)

 $(3,546,766

)


  

Three Months ended
March 31,

 
  

2019

  

2018

 
         

Basic Numerator:

        
         

Net loss

 $(1,803,508

)

 $(2,191,992

)

Convertible preferred stock dividends

  -   (156,162

)

Net loss available to common stockholders (basic and diluted)

 $(1,803,508

)

 $(2,348,154

)

 

The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the net losses for the three and six months ended June 30, 2018March 31, 2019 and 2017:2018:

 

  

Three Months ended

June 30,

  

Six Months ended

June 30,

 
  

2018

  

2017

  

2018

  

2017

 
                 

Preferred stock

  1,200,767   5,416,667   2,853,513   5,416,667 

Stock options

  37,015   35,706   19,863   44,580 

Warrants

  -   3,004   -   3,336 

Total

  1,237,782   5,455,377   2,873,376   5,464,583 

Three Months ended
March 31,

2019

2018

Preferred stock

-4,506,259

Stock options

-4,542

Warrants

--

Total

-4,510,801

  

ItemsThe following table sets forth options and warrants which were excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

 

 

Three Months ended

June 30,

  

Six Months ended

June 30,

  

Three Months Ended
March 31,

 
 

2018

  

2017

  

2018

  

2017

  

2019

  

2018

 
                        

Stock options

  1,366,467   218,761   1,445,891   218,761   1,794,737   1,468,325 

Warrants

  1,398,969   1,212,163   1,398,969   1,212,163   3,780,976   1,398,969 

Total

  2,765,436   1,430,924   2,844,860   1,430,924   5,575,713   2,867,294 

 


  

 

10.12.

STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $.0001 par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications. As of June 30, 2018,March 31, 2019, 100,000 shares of preferred stock have been designated as Series A-1 Convertible Preferred Stock, of which 90,000 were issued in 2015 and 0 shares are issued andremain outstanding, and 105,000 shares of preferred stock have been designated as Series B-1 Convertible Preferred Stock, of which 105,000 were issued in 2015 and 0 are issued andremain outstanding.  

        

Series A-1 Convertible Preferred Stock

  

On October 22 and 29, 2015, the Company issued 84,500 shares of Series A-1 Convertible Preferred Stock (“Series A-1 Stock”) at a purchase price of $100.00 per share, for aggregate gross proceeds of $8,450,000. On November 11, 2015, 5,500 additional shares of Series A-1 Convertible Preferred Stock were issued at a purchase price of $100.00 per share, for gross cash proceeds of $550,000. Shares of Series A-1 Stock are convertible at any time at the option of the holder into shares of common stock by dividing the Series A-1 Original Issue Price by an initial conversion price of $3.60 per share, subject to adjustment for stock dividends, stock splits, combinations, and reclassifications of the Company’s capital stock, and subject to a “blocker provision” which prohibits conversion if such conversion would result in the holder being the beneficial owner of in excess of 9.99% of the Company’s common stock.   In connection with the request of the sole holder of the Series A-1 Stock, on August 7, 2017 the Company waived a standstill agreement to permit the holder to increase his conversion cap to 35% effective 61 days after such waiver request. The Series A-1 Stock accrues dividends at the rate of 6% per annum payable quarterly on April 1, July, 1, October 1, and January 1 of each year. Until October 1, 2017, the dividends were payable in cash provided that if payment in cash would be prohibited under applicable Delaware corporation law or cause the Company to breach any agreement for borrowed money, such dividends are payable in kind through the issuance of additional shares of common stock having a value equal to the volume weighted average trading price of the Company’s common stock for the ten (10) days preceding the applicable dividend payment date. Commencing January 1, 2018, dividends are payable at the option of the Company in cash or kind through the issuance of additional shares of common valued as described above.

The holders of the Series A-1 Stock are entitled to designate one person to serve on the Board of Directors of the Company.  The holders of the Series A-1 Stock are entitled to vote on an as converted to common stock basis together with the holders of our common stock on all matters presented to our stockholders. Upon any liquidation or dissolution of the Company, any merger or consolidation involving the Company or any subsidiary of the Company in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation do not represent immediately following such merger or consolidation at least a majority of the voting power of the capital stock of the resulting or surviving corporation, or the sale of all or substantially all assets in a single transaction or a series of related transactions, unless the holders of at least a majority of the outstanding Series A-1 Stock elect otherwise, holders of Series A-1 Stock shall be entitled to receive prior to any payment to any holders of the Company’s common stock an amount per share equal to $100.00 per share plus any declared and unpaid dividends (pari-passu with the Series B-1 holders). 


 

Between September 22, 2017 and May 31, 2018, the holder of the Series A-1 Stock converted all shares of Series A-1 Stock into an aggregate of 2,500,000 shares of common stock and purchased an aggregate of 248,893 shares of common stock in consideration of the conversion of $896,015 of accrued dividends payable on the Series A-1 Stock

 

As a result of the forgoing conversions, there are no longer any issued and outstanding shares of Series A-1 Stock.Stock as of March 31, 2019.

 

Overall balances and conversion of Series A-1 shares and accrued dividends into common stock has been as follows:

 

 

Series A-1

  

Accrued Dividends

  

Series A-1

  

Accrued

Dividends

 
                

Balance – January 1, 2017

  90,000  $270,000   90,000  $270,000 

Accrual of dividends – Q1 2017

      135,000   -   135,000 

Accrual of dividends – Q2 2017

      135,000   -   135,000 

Accrual of dividends – Q3 2017

      135,000   -   135,000 

Conversion into common stock – September 2017

  -   (540,000

)

  -   (540,000

)

Conversion into common stock – October 2017

  (27,404

)

  -   (27,404

)

  - 

Accrual of dividends – Q4 2017

      101,658       101,658 

Balance – December 31, 2017

  62,596  $236,658   62,596  $236,658 

Accrual of dividends – Q1 2018

      93,894   -   93,894 

Conversion into common stock – April 2018

  (39,088

)

  (330,552

)

  (39,088

)

  (330,552

)

Accrual of dividends – Q2 2018 (until final conversion)

      25,463   -   25,463 

Conversion into common stock – May 2018

  (23,508

)

  (25,463

)

  (23,508

)

  (25,463

)

Balance – June 30, 2018

  -  $- 

Balance – December 31, 2018

  -  $- 

 

The Series A-1 Stock contains options that based on an evaluation of FASB ASC 815-15, “Embedded Derivatives” and FASB ASC 815-40-15, “Contracts in Entity’s Own Equity - Scope and Scope Exceptions,” are considered embedded features:  Preferred Stock’s conversion option:  The Series A-1 Stock is convertible at the holder’s option at any time at the fixed conversion price of $3.60 per share; Quarterly Dividend Conversion Option:  From issuance until December 31, 2017, the majority of holders could have  elected to have the quarterly dividend payment made in shares of common stock, having a value equal to the volume weighted average trading price of the common stock during the ten (10) trading day period preceding the applicable dividend payment date. These features were analyzed by the Company and determined that they were not required to be bifurcated from the preferred stock and recorded as derivatives as they are clearly and closely related to an equity host.

Series B-1 Convertible Preferred Stock

  

On November 11, 2015, the Company issued 105,000 shares of Series B-1 Convertible Preferred Stock (the “Series B-1 Stock”) at a purchase price of $100.00 per share, for gross proceeds of $10,500,000.  Shares of the Series B-1  Stock are convertible at any time at the option of the holder into shares of common stock by dividing the Series B-1 Original Issue Price by an initial conversion price of $3.60 per share, subject to adjustment for stock dividends, stock splits, combinations, and reclassifications of the Company’s capital stock, and subject to a “blocker provision” which prohibits conversion if such conversion would result in the holder being the beneficial owner of in excess of 9.99% of the Company’s common stock.  During a conversion detailed in the table below, the Company waived a standstill provision to permit a holder of Series B-1 Stock to increase conversion limitation to 19.99% of the Company's issued and outstanding shares of common stock to be effective 61 days after such waiver.  The Series B-1 Stock accrues dividends at the rate of 2.5% per annum payable quarterly on April 1, July, 1, October 1, and January 1 of each year payable in cash provided that if payment in cash would be prohibited under applicable Delaware corporation law or cause the Company to breach any agreement for borrowed money, or if the majority of the outstanding shares of the Series B-1 Stock elect otherwise, such dividends are payable in kind through the issuance of additional shares of common stock having a value equal to the volume weighted average trading price of the Company’s common stock for the ten (10) days preceding the applicable dividend payment date. 


The holders of the Series B-1 Stock are entitled to designate one person to serve on the Board of Directors of the Company. The holders of the Series B-1 Stock are entitled to vote on an as converted to common stock basis together with the holders of our common stock on all matters presented to our stockholders. Upon any liquidation or dissolution of the Company, any merger or consolidation involving the Company or any subsidiary of the Company in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation do not represent immediately following such merger or consolidation at least a majority of the voting power of the capital stock of the resulting or surviving corporation, or the sale of all or substantially all assets in a single transaction or a series of related transactions, unless the holders of at least a majority of the outstanding Series B-1 Stock elect otherwise, holders of Series B-1 Stock shall be entitled to receive prior to any payment to any holders of the Company’s common stock an amount per share equal to $100.00 per share plus any declared and unpaid dividends (pari-passu with the Series A-1 holders).  

 

Between March 23, 2018 and May 23, 2018, holders of shares of Series B-1 Stock converted all shares of Series B-1 Stock into an aggregate of 2,916,668 shares of common stock and purchased an aggregate of 131,230131,229 shares of common stock in consideration of the conversion of $472,426 of accrued dividends payable on the Series B-1 Stock.

 


As a result of the forgoing conversions, there are no longer any issued and outstanding shares of Series B-1 Stock.Stock as of March 31, 2019.

 

Overall balances and conversion of Series B-1 shares and accrued dividends into common stock has been as follows:

 

  

Series B-1

  

Accrued Dividends

 
         

Balance – January 1, 2017

  105,000  $131,250 

Accrual of dividends – Q1 2017

      65,625 

Accrual of dividends – Q2 2017

      65,625 

Accrual of dividends – Q3 2017

      65,625 

Accrual of dividends – Q4 2017

      65,625 

Balance – December 31, 2017

  105,000   393,750 

Conversion into common stock – March 2018

  (60,420

)

  (417,084

)

Accrual of dividends – Q1 2018

      62,268 

Accrual of dividends – Q2 2018 (until final conversion)

      16,408 

Conversion into common stock – May 2018

  (44,580

)

  (55,342

)

Balance – June 30, 2018

  -  $- 

The Series B-1 Stock contains options that based on an evaluation of FASB ASC 815-15, “Embedded Derivatives” and FASB ASC 815-40-15, “Contracts in Entity’s Own Equity - Scope and Scope Exceptions,” are considered embedded features:  Preferred Stock’s conversion option:  The Series B-1 Stock is convertible at the holder’s option at any time at the fixed conversion price of $3.60 per share; Quarterly Dividend Conversion Option:  The majority of holders may elect to have the quarterly dividend payment made in shares of common stock, having a value equal to the volume weighted average trading price of the common stock during the ten (10) trading day period preceding the applicable dividend payment date. These features were analyzed by the Company and determined that they were not required to be bifurcated from the preferred stock and recorded as derivatives as they are clearly and closely related to an equity host.  


  

Series B-1

  

Accrued

Dividends

 
         

Balance – January 1, 2017

  105,000  $131,250 

Accrual of dividends – Q1 2017

  -   65,625 

Accrual of dividends – Q2 2017

  -   65,625 

Accrual of dividends – Q3 2017

  -   65,625 

Accrual of dividends – Q4 2017

  -   65,625 

Balance – December 31, 2017

  105,000   393,750 

Conversion into common stock – March 2018

  (60,420

)

  (417,084

)

Accrual of dividends – Q1 2018

  -   62,268 

Accrual of dividends – Q2 2018 (until final conversion)

  -   16,408 

Conversion into common stock – May 2018

  (44,580

)

  (55,342

)

Balance – December 31, 2018

  -  $- 

 

Common Stock

 

On March 23, 2018, in addition to the conversion of Series B-1 Stock21 and accrued dividends payable into a total of 1,794,191 shares of common stock,28, 2019, the Company issued 7,65913,820 shares of common stock to its directors in payment of board and board committee fees valued at $15,011.  

On March 28, 2018, the Company issued 762 shares of common stock to its directors in payment of committee fees valued at $1,501.

On April 3, 2018, the holder of Series A-1 Stock converted shares and accrued dividends payable into a total of 1,177,598 shares of common stock.

On May 10, 2018, the Company issued 2,035 shares of common stock to its directors in payment of board fees.  

On May 14, 2018, the Company issued 648 shares of common stock to its directors in payment of committee fees.

On May 23, 2018, the holders of Series B-1 Stock converted shares and accrued dividends payable into a total of 1,253,707 shares of common stock.

On May 31, 2018, the holder of Series A-1 Stock converted shares and accrued dividends payable into a total of 660,073 shares of common stock.

Derivative Liabilities

In connection with the issuances of equity instruments or debt, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities, rather than as equity. In addition, the equity instrument or debt may contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company early-adopted the new provisions issued July 2017, for derivative liability instruments under FASB ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Under ASU 2017-11, down round features do not meet the criteria for derivative accounting and no liability is to be recorded until an actual issuance of securities triggers the down-round feature. Prior to these provisions, the liabilities were recorded without the actual issuance of the securities triggering the down-round feature.$16,506. 

 

Securities Purchase Agreement dated November 13, 2014

 

Pursuant to a Securities Purchase Agreement, dated November 13, 2014, by and between the Company and a number of private and institutional investors, the Company issued to certain private investors 664,584 shares of common stock and warrants to purchase an additional 996,877 shares of common stock for aggregate gross proceeds of $1,595,000.

 

The warrants have a term of five years and an initial exercise price of $3.60 per share, and have been fully exercisable since February 2015. The warrants have customary anti-dilution protections including a “full ratchet” anti-dilution adjustment provision which are triggered in the event the Company sells or grants any additional shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than $3.60 per share, The anti-dilution adjustment provision is not triggered by certain “exempt issuances” which among other issuances, includes the issuance of shares of common stock, options or other securities to officers, employees, directors, consultants or service providers.

 

AsPursuant to the Underwriting Agreement with Maxim Group, on August 24, 2018 the Company issued Common Stock and Warrants to investors at a resultpurchase price of $1.50 per unit which triggered the early adoptionanti-dilution protection provision under this Securities Purchase Agreement. Due to this provision, the total number of ASU 2017-11,outstanding and fully vested warrants was increased from 996,877 to 2,392,502, and the “full ratchet” anti-dilution feature is no longerexercise price was reduced from $3.60 to $1.50 per share. The Company recognized a determinant for derivative liability accounting. As the “full ratchet” anti-dilution feature was determined to have no valuenon-cash deemed dividend of $1,288,139 in the past, the adoption had no effect on the balance sheets or statements of operations. connection with these adjustments.


 

Securities Purchase Agreement dated September 23, 2015

 

On September 23, 2015, the Company issued a warrant to purchase 69,445 shares of common stock in connection with the issuance of a promissory note. The warrants are immediately exercisable at an initial exercise price of $3.60 per share and have a term of five years. 


 

The warrants have customary anti-dilution protections including a "full ratchet" anti-dilution adjustment provision which are triggered in the event the Company sells or grants any additional shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than $3.60 per share. The anti-dilution adjustment provision is not triggered by certain "exempt issuances" which among other issuances, includes the issuance of shares of common stock, options or other securities to officers, employees, directors, consultants or service providers.

 

AsPursuant to the Underwriting Agreement with Maxim Group, on August 24, 2018 the Company issued Common Stock and Warrants to the investors at a resultpurchase price of $1.50 per unit which triggered the early adoptionanti-dilution protection provision under this Securities Purchase Agreement. Due to this provision, the total number of ASU 2017-11,outstanding and fully vested warrants for the “full ratchet” anti-dilution feature is no longerinvestor was increased from 69,445 to 166,668, and the exercise price was reduced from $3.60 to $1.50 per share. The Company recognized a determinant for derivative liability accounting. As the “full ratchet” anti-dilution feature was determined to have no valuenon-cash deemed dividend of $140,827 in the past, the adoption had no effect on the balance sheets or statements of operations.connection with these adjustments.

 

Issuances of Stock Options

 

On March 23, 2018,21, 2019, the Company issued options to purchase 9,000235,334 shares of common stock to six non-employee members of the Board of Directors.  The options have a three year vesting period, seven year term, and exercise price of $1.96.  

On March 23, 2018, the Company issued options to purchase 212,918 shares of the Company’s common stock to certain officers, employees, and contractors. The options have a three year vesting period, seven year term, and exercise price of $1.96.$1.18.  

 

The fair value of the options issued during the three months ended March 31, 20182019 was estimated on the date of grant at $381,876$243,643 using the Black-Scholes option-pricing model with the following assumptions: risk free interest rate: 2.56%2.35%, expected life of options in years: 4.5, expected dividends: 0, volatility of stock price: 143%.

 

There were no additional options issued during the three months ended June 30, 2018.

  

 

11.13.

SEGMENT INFORMATION

 

The Company has determined that its continuing operations areit operates in one discrete segment consisting of biometric products. Geographically, North American sales accounted for approximately 56%46% and 58%52% of the Company’s total sales for the three monthsthree-month periods ended June 30,March 31, 2019 and 2018, and 2017, respectively, and were approximately 54% and 73% of the Company’s total sales for the six months ended June 30, 2018 and 2017, respectively.

  

 

 

12.14.

FAIR VALUES OF FINANCIAL INSTRUMENTS

 

Cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, andinventory, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature.

 

 

 

13.15.

MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLERECEIVABLES

 

For the three months ended June 30,March 31, 2019 and 2018, and 2017, two customers accounted for 34%56% of revenues and three customers accounted for 52% of revenue, respectively. For the six months ended June 30, 2018 and 2017, two customers accounted for 37% and three customers48% of revenues, respectively. One customer accounted for 44% of revenue, respectively.

Four customers accounted for 53%74% of current accounts receivable as of June 30, 2018. March 31, 2019. At December 31, 2018, one customer accounted for 70% of current accounts receivable.


One customer accounted for 100% of non-current accounts receivable as of June 30, 2018March 31, 2019 and December 31, 2017. Based on prior history with this customer, the Company believes the amount is fully collectable, however, the Company has reserved $1,000,0002018 which represents 58% of the remaining balance owed under the contract, due to the length of time the receivable has been outstanding.  At December 31, 2017, one customer accounted for 55% of current accounts receivable.100% reserved for.

 

 

 

14.16.

SUBSEQUENT EVENTS

 

On August 9, 2018,April 4, 2019, the Company issued 3,282a $550,000 secured convertible debenture which matures November 15, 2019 and is convertible into common stock at a conversion price of $1.50 per share.  The debenture may be redeemed at any time by payment of a premium to the principal balance starting at 5% and increasing to 20%.  The debenture was issued at a 7% original issue discount.  Subject to the mutual agreement of the Company and the investor, the Company may purchase two additional $550,000 principal amount debentures on the same terms after 45 day intervals from the prior issuance, totaling a potential $1,650,000.  At the closing, the Company issued 80,000 shares of common stock in payment of a $120,000 commitment fee and is obligated to issue 10,000 shares of common stock monthly in payment of a monthly commitment fee of $15,000 until the earlier of November 1, 2019 or the repayment or conversion of the debenture.

On May 14, 2019, the Company issued 4,235 shares of common stock to its directors in payment of committee and board fees.

The Company has reviewed all other subsequent events through the date of filing. 

 


 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition between us and other companies in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to expand into the Asian market; delays in the development of products and statements of assumption underlying any of the foregoing, as well as other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition between us and other companies in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to expand into the Asian market; delays in the development of products and statements of assumption underlying any of the foregoing, as well as other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.OPERATIONS.

 

The following discussionThis Management’s Discussion and analysisAnalysis of Financial Condition and Results of Operations summarizes the significant factors affecting the operating results, financial condition, liquidity and cash flows of ourthe Company as of and for the periods presented belowbelow. The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and related information contained herein and in our audited financial statements as of December 31, 2017.2018.

 

OVERVIEW

 

We developBIO-key International, Inc. (the “Company”, “we” or “us”) develops and marketmarkets advanced fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing fingerprint biometric hardware and software solutions. We were pioneers in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit card, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing.  Advanced BIO-key technology has been and is used to improve both the accuracy and speed of competing finger-based biometrics. Our solutions are used by many customers in every sector of our economy including government, retail, healthcare and financial services.

 

In partnerships with OEMs, integrators, and solution providers, we provide biometric software solutions to private and public sector customers.  We provide the ability to positively identify and authenticate individuals before granting access to valuable corporate resources, web portals or applications in seconds.  Powered by our patented Vector Segment Technology (VST™), or VST, WEB-key and BSP development kits are fingerprint biometric solutions that provide interoperability with all major reader manufacturers, enabling application developers and integrators to integrate fingerprint biometrics into their applications. 

 

We also develop and distribute hardware components that are used in conjunction with our software, and sell third-party hardware components with our software in various configurations required by our customers. Our products are interoperable with all major fingerprint reader and hardware manufacturers and across Windows, Linux, and the Android mobile operating systems enabling application developers, value added resellers, and channel partners to integrate our fingerprint biometrics into their applications, while dramatically reducing maintenance, upgrade and life-cycle costs. 

We support industry standards, such as FIDO, BioAPI, and have received National Institute of Standards and Technology independent laboratory certification of our ability to support Homeland Security Presidential Directive #12 (HSPD-12) and ANSI/INCITS-378 templates, as well as validation of our fingerprint match speed and accuracy in large database environments. 

We have developed what we believe is the most discriminating and effective commercially available finger-based biometric technology. Our primary focus is in marketing and selling this technology into commercial logical and physical privilege entitlement & access control markets.  Our primary market focus includes, among others, enterprise access, mobile payments & credentialing, online payments, and healthcare record and payment data security.  Our secondary focus includes government and educational markets.

Products

In 2016, we began to sell through distributorsdistribution and directly to consumers and commercial users our SideSwipe, SideTouch and EcoID products. SideSwipe, SideTouch and EcoID are stand-alone fingerprint readers that can be used on any laptop, tablet or other device with a USB port. In 2017, we expanded our consumer product line to include biometric and blue tooth enabled pad locks, TSA approved luggage locks, and bicycle locks. In 2018, we introduced OmniPass Consumer, a secure biometric-enabled application to manage multiple passwords for online apps, services or accounts.

 

In 2015, Microsoft announced native support for biometrics in the Windows 8.1 and Windows 10 Operating platforms as well as Office 2016. With Microsoft Hello, any user can replace their PIN or password to access their device without any special software downloads by using our finger scanners, SideSwipe, SideTouch and EcoID, which are plug and play compatible with the Microsoft platforms. We have developed whatbeen the preferred partner, in particular at the Microsoft “Ignite your Business” Windows 10 and Office 2016 launch events, which has generated a number opportunities for both our hardware and software offerings. In 2016, our finger scanners were tested and qualified by Microsoft, then introduced and are sold in the Microsoft stores nationwide, as well as through their on-line channel. 

In 2018, we believe is the most discriminatingcontinued to invest and effective commercially available finger-based biometric technology. Our primary focus is in marketing and sellinggrow our technology into commercial logical and physical privilege entitlement & access control markets and our products in both consumer and commercial markets.  Our primary market focus includes, among others, enterprise access, mobile payments & credentialing, online payments, and healthcare record and payment data security.  Our secondary focus includes government and educational markets.relationship with Microsoft. The 2018 Ignite your Business event included Microsoft hosting an exclusive BIO-key demonstration kiosk within their event showcase.

 


 

STRATEGIC OUTLOOK AND RECENT DEVELOPMENTS

 

Historically, our largest market has been access control within highly regulated industries such as healthcare.  However, we believe the mass adoption of advanced smart-phone and hand-held wireless devices have caused commercial demand for advanced user authentication to emerge as viable.  The introduction of smart-phone capabilities, like mobile payments and credentialing, could effectively require biometric user authentication on mobile devices to reduce risks of identity theft, payment fraud and other forms of fraud in the mobile or cellular based world wide web. As more services and payment functionalities, such as mobile wallets and near field communication (NFC), migrate to smart-phones, the value and potential risk associated with such systems should grow and drive demand and adoption of advanced user authentication technologies, including fingerprint biometrics and BIO-key solutions.

 

As devices with onboard fingerprint sensors continue to deploy to consumers, we expect that third party application developers will demand the ability to authenticate users of their respective applications (app’s) with the onboard fingerprint biometric. We further believe that authentication will occur on the device itself for potentially low-value, and therefore low-risk, use-transactions and that user authentication for high-value transactions will migrate to the application provider’s authentication server, typically located within their supporting technology infrastructure, or Cloud. We have developed our technology to enable, on-device authentication as well as network or cloud-based authentication and believe we may be the only technology vendor capable of providing this flexibility and capability.

Our core technology works on over 40 commercially available fingerprint readers, across both Windows and Linux platforms, and Apple iOS and Android mobile operating systems. This interoperability, coupled with the ability to authentic users via the device or cloud, is unique in the industry, provides a key differentiator for us, and in our opinion, makes our technology more viable than competing technologies and expands the size of the overall market for our products.

 

We believe there is potential for significant market growth in the following key areas:

 

Corporate network access control, including corporate campuses, computer networks, and applications;applications.

 

 

Government funded initiatives, including with the state board of elections.

International government use case applications as prospects see us as a global leader in the biometric technology space as witnessed by our agreement with the Israeli Defense Force, and the Singapore and Dubai Police departments.


Consumer mobile credentialing, including mobile payments, credit and payment card programs, data and application access, and commercial loyalty programs;programs. 

 

  

Demand for BIO-key hardware products from Windows 10 users and Fortune 500 companies.

 

Government services and highly regulated industries including, Medicare, Medicaid, Social Security, drivers’ licenses, campusDrivers Licenses, Campus and schoolSchool ID, passports/visas;Passports/Visas.

 

  

Direct sales of fingerprint readers to consumers and commercial customers;

Growth in the Asia Pacific region; andregion.

 

  

Biometric based consumer products.

 

In the near-term, we expect to grow our business within government services and highly-regulated industries in which we have historically had a strong presence, such as the healthcare industry.  We believe that continued heightened security and privacy requirements in these industries will generate increased demand for security solutions, including biometrics. In addition, we expect that the integration of our technology into Windows 10, will accelerate the demand for our computer network log-on solutions and fingerprint readers. Finally, our entry into the Asian market and licensing arrangement with CGG has further expanded our business by opening new markets along with the new and innovative hardware offerings. We expect our SideSwipe, EcoID and SideTouch finger readers, and our biometric and Bluetooth enabled padlocks, luggage locks, and bicycle locks to continue to drive incremental revenue and growth.

 

We intend to expand our business into the cloud and mobile computing industries. The emergence of cloud computing and mobile computing are primary drivers of commercial and consumer adoption of advanced authentication applications, including biometric and BIO-key authentication capabilities.  As the value of assets, services and transactions increases on such networks, we expect that security and user authentication demand should rise proportionately. Our integration partners include major web and network technology providers, who we believe will deliver our cloud-applicable solutions to interested service-providers. These service-providers could include, but are not limited to, financial institutions, web-service providers, consumer payment service providers, credit reporting services, consumer data service providers, healthcare providers and others. Additionally, our integration partners include major technology component providers and OEM manufacturers, who we believe will deliver our device-applicable solutions to interested hardware manufacturers. Such manufacturers could include cellular handset and smartphone manufacturers, tablet manufacturers, laptop and PC manufacturers, among other hardware manufacturers. Our recently introduced SAML (Security Assertion Markup Language) and Open ID solutions will create new opportunities for us in 2018.2019. 


 

CRITICAL ACCOUNTING POLICIES

 

For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K for the year ended December 31, 2017.2018.  There have been no material changes to our critical accounting policies (except where described in note 3) and estimates from those disclosed in our most recent Annual Report on Form 10-K. 10-K, except for adoption of Leases (ASC 842) – refer Note 1.

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

For detailed information regarding recent account pronouncements, see Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

 


 

RESULTS OF OPERATIONS

 

THREE MONTHS ENDED JUNE 30,MARCH 31, 20189 AS COMPARED TO JUNE 30,MARCH 31, 20178

 

Consolidated Results of Operations - Percent Trend

 

  

Three Months Ended June 30,

 
  

2018

  

2017

 

Revenues

        

Services

  33

%

  15

%

License fees

  21

%

  14

%

Hardware

  46

%

  71

%

Total Revenues

  100

%

  100

%

Costs and other expenses

        

Cost of services

  16

%

  6

%

Cost of license fees, hardware, and other

  121

%

  84

%

Total Cost of Goods Sold

  138

%

  90

%

Gross profit

  -38

%

  10

%

         

Operating expenses

        

Selling, general and administrative

  144

%

  161

%

Research, development and engineering

  40

%

  51

%

Total Operating Expenses

  184

%

  212

%

Operating loss

  -221

%

  -202

%

         

Other income

  0

%

  0

%

         

Net loss

  -221

%

  -202

%

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

Revenues

 

 

 

 

 

 

 

 

Services

 

 

44

%

 

 

36

%

License fees

  

15

%

  

12

%

Hardware

 

 

41

%

 

 

52

%

Total Revenues

 

 

100

%

 

 

100

%

Costs and other expenses

 

 

 

 

 

 

 

 

Cost of services

 

 

16

%

 

 

18

%

Cost of license fees and hardware

 

 

94

%

 

 

122

%

Total Cost of Goods Sold

 

 

110

%

 

 

140

%

Gross profit

 

 

-10

%

 

 

-40

%

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

249

%

 

 

174

%

Research, development and engineering

 

 

68

%

 

 

46

%

Total Operating Expenses

 

 

317

%

 

 

220

%

Operating loss

 

 

-327

%

 

 

-261

%

 

 

 

 

 

 

 

 

 

Other income (expenses)

 

 

-

%

 

 

-

%

 

 

 

 

 

 

 

 

 

Net loss

 

 

-327

%

 

 

-261

%

 

Revenues and cost of goods sold

 

  

Three months ended

June 30,

         
  

2018

  

2017

  

$ Change

  

% Change

 
                 

Revenues

                

Service

 $249,121  $134,061  $115,060   86

%

License

  154,251   127,751   26,500   21

%

Hardware

  344,769   625,069   (280,300

)

  -45

%

Total Revenue

 $748,141  $886,881  $(138,740

)

  -16

%


 

Three months ended

June 30,

          

Three months ended

         
 

2018

  

2017

  

$ Change

  

% Change

  

March 31,

         

Cost of Goods Sold

                
 

2019

  

2018

  

$ Change

  

% Change

 
                

Revenues

                

Service

 $120,841  $55,660  $65,181   117

%

 $241,610  $302,449  $(60,839

)

  -20

%

License, hardware, & other

  908,962   740,301   168,661   23

%

License

  83,208   102,719   (19,511

)

  -19

%

Hardware

  226,805   436,287   (209,482

)

  -48

%

Total Revenue

 $551,623  $841,455  $(289,832

)

  -34

%

                

Cost of goods sold

                

Service

 $90,829  $154,733  $(63,904

)

  -41

%

License & Hardware

  513,221   1,024,712   (511,491

)

  -50

%

Total COGS

 $1,029,803  $795,961  $233,842   29

%

 $604,050  $1,179,445  $(575,395

)

  -49

%

 

Revenues

 

For the three months ended June 30, 2018 and 2017,March 31, 2019, service revenues included approximately $241,000 and $124,000, respectively,were $241,610 as compared to $302,449 during the three months ended March 31, 2018, a decrease of $60,839, or 20%. The decrease was due to non-recurring custom service revenue decreasing to $2,750 as compared to $101,850 during the three months ended March 31, 2018, resulting primarily from the end of a project for custom services to one customer. The decrease was offset by recurring maintenance and support revenue increasing to approximately $238,900 as compared to $200,600 during the three months ended March 31, 2018, attributable largely to maintenance and approximately $8,000 and $10,000 respectively,support of non-recurring custom services revenue.  Recurring service revenue increased 95%a large license order shipped in 2018 as we continued to bundle maintenance agreements to our expanding customer license base, including one large new customer and renewed existing maintenance agreements from our legacy customers. Non-recurring custom services decreased 22% for custom services due to fewer customized installations.December of 2017.

  

For the three months ended June 30, 2018 and 2017,March 31, 2019, license revenue increased 21%decreased to $83,208 or 19% from the corresponding period in 2017. The higher revenue included revenue from both new and existing customers. 

For$102,719 during the three months ended June 30, 2018, hardwareMarch 31, 2018. The decrease was due to an increase in new customers with smaller initial orders. During the three months ended March 31, 2019, we continued to ship products to Omnicell (formerly Aesynt) for the continued deployment of our identification technology in its AccuDose® product line, and for continued expansion of biometric ID deployments with several commercial partners, including several healthcare facilities and banks.


Hardware sales decreased during the three months ended March 31, 2019 by 45%approximately $209,500, or 48%, as a resultto $226,805 from $436,287 during the three months ended March 31, 2018. The decrease resulted from an approximate $116,000 reduction in the shipment of smaller new customer deploymentslocks and an increased volumeapproximate $94,000 reduction in shipments of fingerprint readers due to smaller lock orders. orders in 2019 as compared to 2018.

 

Costs of goods sold

 

For the three months ended June 30, 2018,March 31, 2019, cost of service increased 117%, duedecreased approximately $64,000 or 41% to engineering support for maintenance services. 

License, hardware, and other costs for$90,829, as a result of no large custom services orders, compared to the three months ended June 30,March 31, 2018 increased approximately 23%. The increase was directlywhere costs of outside contractors and reclassed research and development resources to cost of goods sold were included. For the three months ended March 31, 2019, license and hardware decreased to $513,221 from $1,024,712 during the three months ended March 31, 2018, related to lower costs associated with theless hardware revenue, and a decrease of approximately $379,000 in amortization of the software rights.rights which is included in cost of license fees on the statement of operations.

 

Selling, general and administrative

 

  

Three months ended

June 30,

         
  

2018

  

2017

  

$ Change

  

% Change

 
                 

Selling, general and administrative

 $1,076,184  $1,431,208  $(355,024

)

  -25

%

  

Three months ended

         
  

March 31,

         
  

2019

  

2018

  

$ Change

  

% Change

 
                 

Selling, general and administrative

 $1,377,033  $1,461,854  $(84,821

)

  -6

%

 

Selling, general and administrative costsexpenses for the three months ended June 30, 2018March 31, 2019 decreased 25% from6% to $1,377,033 as compared to $1,461,854 for the corresponding period in 2017.2018.   The decrease is attributablewas due to reducedlower personnel expenses, factoring fees, personnel and related costs, and commitment fees, which wasnon-cash, share-based compensation costs. These amounts were offset by higher non-cash compensation,an increases in commission expense, franchise tax expense, accounting and legal fees.  fees, show attendance and booth costs.

  

Research, development and engineering

 

  

Three months ended

June 30,

         
  

2018

  

2017

  

$ Change

  

% Change

 
                 

Research, development and engineering

 $297,633  $449,049  $(151,416

)

  -34

%

  

Three months ended

         
  

March 31,

         
  

2019

  

2018

  

$ Change

  

% Change

 
                 

Research, development and engineering

 $374,118  $392,154  $(18,036

)

  -5

%

 

For the three months ended June 30, 2018,March 31, 2019, research, development and engineering costsexpenses decreased 34%5% to $374,118 as compared to $392,154 for the corresponding period in 2017, as a result of decreased temporary outside services, and2018. Included in the decrease were reductions in personnel expense, non-cash, share-based compensation costs, and related costs.


SIX MONTHS ENDED JUNE 30, 2018 AS COMPARED TO JUNE 30, 2017

Consolidated Results of Operations - Percent Trend

  

Six Months Ended June 30,

 
  

2018

  

2017

 

Revenues

        

Services

  35

%

  20

%

License fees

  16

%

  27

%

Hardware

  49

%

  53

%

Total Revenues

  100

%

  100

%

Costs and other expenses

        

Cost of services

  17

%

  4

%

Cost of license fees, hardware, and other

  122

%

  59

%

Total Cost of Goods Sold

  139

%

  63

%

Gross profit

  -39

%

  37

%

         

Operating expenses

        

Selling, general and administrative

  160

%

  132

%

Research, development and engineering

  43

%

  41

%

Total Operating Expenses

  203

%

  173

%

Operating loss

  -242

%

  -136

%

         

Other income

  0

%

  0

%

         

Net loss

  -242

%

  -136

%

Revenues and cost of goods sold

  

Six months ended

June 30,

         
  

2018

  

2017

  

$ Change

  

% Change

 

Revenues

                

Service

  551,570   454,648   96,922   21

%

License

  256,970   624,319   (367,349

)

  -59

%

Hardware

  781,056   1,226,249   (445,193

)

  -36

%

Total Revenue

 $1,589,596  $2,305,216  $(715,620

)

  -31

%

                 

Cost of Goods Sold

                

Service

  275,573   94,480   181,093   192

%

License, hardware, & other

  1,933,675   1,362,415   571,260   42

%

Total COGS

 $2,209,248  $1,456,895  $752,353   52

%

Revenues

For the six months ended June 30, 2018 and 2017, service revenues included approximately $442,000 and $264,000, respectively, of recurring maintenance and support revenue, and approximately $110,000 and $191,000, respectively, of non-recurring custom services revenue.  Recurring service revenue increase 67% from 2017 as we continued to bundle maintenance agreements to our expanding customer license base including one large new customer and renewed existing maintenance agreements from our legacy customers. Non-recurring custom services decreased 42% for custom services due to fewer customized installations and software.

For the six months ended June 30, 2018, license revenue decreased as a result of the following contributing factors.  First, we received a large orderreductions in the first quarter of 2017 and no comparable orders in the first half of 2018.  Second, although we increased the number of new customer orders in 2018, theycontractor labor. These amounts were for smaller total values. 

For the six months ended June 30, 2018, hardware sales decreased by 36%, as a result of smaller new customer deployments and an increased volume of smaller lock orders. 


Costs of goods sold

For the six months ended June 30, 2018 and 2017, cost of service increased 192%, due to engineering support for customized software and maintenance services. 

License, hardware, and other costs for the six months ended June 30, 2018 increased approximately 42%. The increase was directly associated with the amortization of the software rights.

Selling, general and administrative

  

Six months ended

June 30,

         
  

2018

  

2017

  

$ Change

  

% Change

 
                 

Selling, general and administrative

 $2,538,038  $3,051,358  $(513,320

)

  -17

%

Selling, general and administrative costs for the three months ended June 30, 2018 decreased 17% from the corresponding period in 2017. The decrease is attributable to reduced factoring fees personnel and related expenses, and commitment fees which was offset by higher non-cash compensation,increased research and legal fees.

Research, development and engineering

  

Six months ended

June 30,

         
  

2018

  

2017

  

$ Change

  

% Change

 
                 

Research, development and engineering

 $689,787  $942,493  $(252,706

)

  -27

%

For the six months ended June 30, 2018, research, development and engineering costs decreased 27% from to the corresponding period in 2017, as a result of decreased temporary outside services, personnel and related costs, and recruiting expenses offset by an increase in non-cash compensation costs.

our Hong Kong subsidiary.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Cash Flows

 

Net cash provided by operations during the sixthree months ended June 30, 2018March 31, 2019 was approximately $99,000.$160,000. The cash provided byin operating activities was primarily attributable primarily to the following items:

 

Net positive cash flows related to adjustments for non-cash expenses for depreciation, amortization, share-based compensation, and issuance of common stock to our non-employee directors, and right-of-use assets of approximately $2,130,000,$900,000, and a decrease in accounts receivable, combined with increases in accounts payable, accruals and deferred revenue of approximately $2,424,000.$1,125,000.

 

Net negative cash flows related to payments for liabilities and reductions of deferred revenueprepayments, due from factor, and operating lease liabilities of approximately $552,000.$90,000.

 


Approximately $68,000$25,000 was used for investing activities during the sixthree months ended June 30, 2018March 31, 2019 related to capital expenditures.

 

Approximately $15,000 was used for financing activities during the six months ended June 30, 2018 related to costs of converting the preferred stock to common stock. 

At June 30, 2018, weWe had net working capital at March 31, 2019 of approximately $3,587,000$1,900,000 as compared to net working capital of approximately $4,689,000$3,000,000 at December 31, 2017.  At June 30, 2018, net working capital excluding resalable software license rights was approximately $767,000 as compared to net working capital excluding resalable software license rights of approximately $2,049,000 at December 31, 2017. 2018.


 

Liquidity and Capital Resources

 

Since our inception, our capital needs have been principally met through proceeds from the sale of equity and debt securities.  We expect capital expenditures to be less than $100,000 during the next twelve months.  

 

The following sets forth our primary sources of capital during the previous two years:

 

We entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has since been extended through October 31, 2018.2019. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances per quarter on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us (the “Advance Amount”), with the remaining balance, less fees, to be forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored, and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.   

On November 18, 2016, we issued to Wong Kwok Fong (Kelvin), a director, executive officer and principal stockholder of the Company, 516,667 shares of common stock at a purchase price of $3.60 per share for gross cash proceeds of $1,860,000.

 

On April 28, 2017, we issued to Wong Kwok Fong (Kelvin), a director, executive officer and principal stockholder of the Company, 277,778 shares of common stock at a purchase price of $3.60 per share for gross cash proceeds of $1,000,000.

 

On May 2, 2017, we entered into a committed equity facility pursuant to which we may issue and sell up to $5.0 million worth of shares of common stock, subject to certain limitations and satisfaction of certain conditions, over a 36-month term following the effectiveness of a registration statement covering the public resale of the shares of common stock issued under the facility. As of the date of this report, the registration statement has not been filed. From time to time over the term of the facility, we may issue requests to the investor to purchase a specified dollar amount of shares up to a maximum of $100,000 over a five trading day period based on the daily volume weighted average price of our common stock (VWAP) to the extent the VWAP equals or exceeds the greater of a formula amount or $3.83 per share. The per share purchase price for the shares issued under the facility will be equal to 94% of the lowest VWAP that equals or exceeds $3.83 per share. Aggregate sales under the facility are limited to 19.99% of the total outstanding shares of the Company’s common stock as of May 2, 2017, unless stockholder approval is obtained, and sales under the facility are prohibited if such a sale would result in beneficial ownership by the investor of more than 9.99% of the Company’s common stock. 

 

On September 22, 2017, we issued to Wong Kwok Fong (Kelvin), a director, executive officer and principal stockholder of the Company, 427,778 shares of common stock and warrants to purchase 138,889 shares of common stock for an aggregate purchase price of $1,540,000, or $3.60 per share. The purchase consisted of a cash payment of $1,000,000 and the conversion of accrued dividends payable on the Company’s Series A-1 Convertible Preferred Stock of $540,000.

 

On August 24, 2018, we completed a public offering of units consisting of 1,380,000 shares of common stock and warrants to purchase 1,035,000 shares of common stock for an aggregate gross proceeds of $2,070,000, or $1.50 per unit.

On April 4, 2019, we issued a $550,000 secured convertible debenture to an institutional investor which matures November 15, 2019 and is convertible into common stock at a conversion price of $1.50 per share. The debenture may be redeemed at any time by payment of a premium to the principal balance starting at 5% and increasing to 20%.  The debenture was issued at a 7% original issue discount.  Subject to the mutual agreement of us and the investor, we may purchase up to two additional $550,000 principal amount debentures on the same terms after 45 day intervals from the prior issuance. At the closing, we issued 80,000 shares of common stock in payment of a $120,000 commitment fee and we are obligated to issue 10,000 shares of common stock in payment of a monthly commitment fee of $15,000 until the earlier of November 1, 2019 or the repayment or conversion of the debenture issued on April 4, 2019.

Liquidity outlook

 

At June 30, 2018,March 31, 2019, our total cash and cash equivalents were approximately $304,000,$459,000, as compared to approximately $289,000$324,000 at December 31, 2017.2018.

 

As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We estimate that we currently require approximately $592,000$537,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. During the first halfquarter of 2018,2019, we generated approximately $1,590,000$552,000 of revenue, which is below our average monthly requirements.

 

If we are unable to continue to generate sufficient revenue to meet our goals, we will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute our plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. We expect that we will,may, therefore, need to obtain additional financing through the issuance of debt or equity securities. 


 

Due to several factors, including our history of losses and limited revenue, our independent auditors have included an explanatory paragraph in their opinion related to our annual financial statements as to the substantial doubt about our ability to continue as a going concern. Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or in the extreme case, not continue as a going concern.

 


 

ITEM 4.  CONTROLS AND PROCEDURES

ITEM 4.

CONTROLS AND PROCEDURES. 

 

Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures (asas of March 31, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934)1934, as amended (the “Exchange Act”), means controls and other procedures of June 30, 2018.a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of June 30, 2018,March 31, 2019, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. 

 

Changes in Internal Control Over Financial Reporting

 

No changeThere have been no changes in our internal control over financial reporting occurred during the fiscal quarter ended June 30, 2018,March 31, 2019, that hashave materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting.

 

  

PART II — OTHER INFORMATION

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On May 10, 2018, we issued 2,035 shares of common stock to certain of our non-employee directors in payment of directors’ fees.

On May 14, 2018, we issued 648 shares of common stock to certain of our non-employee directors in payment of board committee fees

The foregoing securities were issued in private placement transactions pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, without general solicitation or advertising of any kind and without payment of placement agent or brokerage fees to any person.

ITEM 6. EXHIBITS

The exhibits listed in the Exhibits Index immediately preceding such exhibits are filed as part of this Report. 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ITEM 6.

BIO-Key International, Inc.

Dated: August 14, 2018

/s/ Michael W. DePasquale

Michael W. DePasquale

Chief Executive Officer

(Principal Executive Officer)

Dated: August 14, 2018

/s/ Cecilia C. Welch

Cecilia C. Welch

Chief Financial Officer

(Principal Financial Officer)EXHIBITS

 


EXHIBIT INDEXThe following exhibits are being filed or furnished with this quarterly report on Form 10-Q.

 

Exhibit

No.

 

Description

31.1

 

Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

 

 

 

31.2

 

Certificate of CFO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended

 

 

 

32.1

 

Certificate of CEO of Registrant required under 18 U.S.C. Section 1350

 

 

 

32.2

 

Certificate of CFO of Registrant required under 18 U.S.C. Section 1350

 

 

 

101.INS

 

XBRL Instance

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition

 

 

 

101.LAB

 

XBRL Taxonomy Extension Labels

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIO-Key International, Inc.

Dated: May 15, 2019

/s/ MICHAEL W. DEPASQUALE

Michael W. DePasquale

Chief Executive Officer

Dated: May 15, 2019

/s/ CECILIA C. WELCH

Cecilia C. Welch

Chief Financial Officer

28